TACSTD2 and cancer: Separate univariable analyses between the four UICC stages revealed that TROP2 expression was solely prognostically relevant in UICC stage III cancers (OS: p = 0.04, HR = 1.57; DSS: p = 0.02, HR = 1.55, DFS: p = 0.02, HR = 1.66), but not in stage I, II, or IV CRC (p = n.s., see supplementary material, Figure S1 for DSS and supplementary material, Figure S2 for OS) or in multivariable analyses.